ABG Innovation Capital Partners III’s Genocea Biosciences, Inc. GNCA Stock Holding History

ABG Innovation Capital Partners III’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-375,000	Closed	-$4K	–	5
2022 Q3	$4K	Hold	375,000	–	–	0.27%	5
2022 Q2	$6K	Hold	375,000	–	–	0.45%	6
2022 Q1	$469K	Hold	375,000	–	–	32.06%	2
2021 Q4	$435K	Hold	375,000	–	–	25.16%	3
2021 Q3	$720K	Hold	375,000	–	–	29.91%	2
2021 Q2	$878K	Hold	375,000	–	–	2.94%	2
2021 Q1	$1.02M	Hold	375,000	–	–	0.5%	3
2020 Q4	$908K	Buy	+375,000	New	+$854K	0.53%	3

ABG Innovation Capital Partners III's GNCA Position: Q4 2022 in Review

ABG Innovation Capital Partners III sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2022, closing a stake of 375,000 shares — an estimated $4K sold.

ABG Innovation Capital Partners III first reported a position in GNCA in Q4 2020 and held it in 8 quarters. The position peaked at $1.02M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNCA as of Q4 2022.

ABG Innovation Capital Partners III reported no remaining Genocea Biosciences, Inc. position as of Q4 2022 after selling out during the quarter.
ABG Innovation Capital Partners III sold 375,000 Genocea Biosciences, Inc. shares in Q4 2022, an estimated $4K.
ABG Innovation Capital Partners III first reported a position in Genocea Biosciences, Inc. in Q4 2020 and held it in 8 quarters.
ABG Innovation Capital Partners III's Genocea Biosciences, Inc. position peaked at $1.02M in Q1 2021.
0 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2022.

Based on ABG Innovation Capital Partners III's 13F filing for Q4 2022, filed 14 Feb 2023.